Contraception
Volume 73, Issue 5 , Pages 493-500 , May 2006

Attitudes, perceptions and knowledge about the vagina: the International Vagina Dialogue Survey

  • Rossella E. Nappi

      Affiliations

    • Research Center for Reproductive Medicine, Department of Obstetrics and Gynaecology, IRCCS Policlinico San Matteo, University of Pavia, 27100 Pavia, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 0382 503846/569; fax: +39 0382 520070.
    • ,
  • Goedele Liekens

      Affiliations

    • St. Amandsstraat 2, 1853 Strombeek-Bever, Belgium
    • ,
  • Ulrike Brandenburg

      Affiliations

    • Klinik für Psychatrie und Psychotherapie, Pauwelstraße 30, D-52074 Aachen, Germany

Received 25 August 2005 ,Revised 5 December 2005 ,Accepted 15 December 2005.

References 

  1. Blackledge C. In: The story of V. London: Phoenix; 2003;p. 1–8
  2. The Association of Reproductive Health Professionals . Vagina dialogues. http://www.arhp.org/vaginadialogues2004;
  3. Hafez ES. The vagina and human reproduction. Am J Obstet Gynecol. 1977;129:573–584
  4. Alexander NJ, Baker E, Kaptein M, Karck U, Miller L, Zampaglione E. Why consider vaginal drug administration?. Fertil Steril. 2004;82:1–12
  5. Rosenberg MJ, Waugh MS, Burnhill MS. Compliance, counseling and satisfaction with oral contraceptives: a prospective evaluation. Fam Plann Perspect 1998;30:89–92, 104.
  6. Rosenberg M, Waugh MS. Causes and consequences of oral contraceptive noncompliance. Am J Obstet Gynecol. 1999;180:S276–S279
  7. Rosenberg MJ, Waugh MS, Meehan TE. Use and misuse of oral contraceptives: risk indicators for poor pill-taking and discontinuation. Contraception. 1995;51:283–288
  8. Kaunitz AM. Oral contraceptive estrogen dose considerations. Contraception. 1998;58:15S–21S
  9. Rosenberg MJ, Waugh MS. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am J Obstet Gynecol. 1998;179:577–582
  10. Roumen FJ, Apter D, Mulders TM, Dieben TO. Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol. Hum Reprod. 2001;16:469–475
  11. Dieben TO, Roumen FJ, Apter D. Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring. Obstet Gynecol. 2002;100:585–593
  12. Oddsson K, Leifels-Fischer B, Wiel-Masson D, et al. Superior cycle control with a contraceptive vaginal ring compared with an oral contraceptive containing 30 microg ethinylestradiol and 150 microg levonorgestrel: a randomized trial. Hum Reprod. 2005;20:557–562
  13. Novak A, de la Loge C, Abetz L, van der Meulen EA. The combined contraceptive vaginal ring, NuvaRing®: an international study of user acceptability. Contraception. 2003;67:187–194
  14. Szarewski A. High acceptability and satisfaction with NuvaRing use. Eur J Contracept Reprod Health Care. 2002;7(Suppl 2):31–36[discussion 37-9]
  15. Soper DE. Genitourinary infections and sexually transmitted diseases. In:  Berek J editors. Novak's gynecology. Philadelphia: Lippincott, William and Wilkins; 2002;p. 453–470
  16. Valore EV, Park CH, Igreti SL, Ganz T. Antimicrobial components of vaginal fluid. Am J Obstet Gynecol. 2002;187:561–568
  17. Zhang J, Thomas AG, Leybovich E. Vaginal douching and adverse health effects: a meta-analysis. Am J Public Health. 1997;87:1207–1211
  18. Ness RB, Hillier SL, Richter HE, et al. Douching in relation to bacterial vaginosis, lactobacilli, and facultative bacteria in the vagina. Obstet Gynecol. 2002;100:765–772
  19. Aubeny E, Buhler M, Colau JC, Vicaut E, Zadikian M, Childs M. Oral contraception: patterns of non-compliance. The Coraliance study. Eur J Contracept Reprod Health Care. 2002;7:155–161
  20. Bajos N, Leridon H, Goulard H, Oustry P, Job-Spira N COCON Group. Contraception: from accessibility to efficiency. Hum Reprod. 2003;18:994–999

PII: S0010-7824(06)00002-3

doi: 10.1016/j.contraception.2005.12.007

Contraception
Volume 73, Issue 5 , Pages 493-500 , May 2006

Article Tools

* Image Usage & Resolution